Long-term supplementation of NMN can increase vascular elasticity

A Japanese clinical trial found that long-term supplementation with NMN can increase vascular elasticity

In 2013, David Sinclair's team at Harvard Medical School found that when 22-month-old mice were supplemented with NMN (niacinamide mononucleotide), their body's key indicators returned to levels similar to those of 6-month-old young mice.

Since then, research on NMN has grown exponentially. After a series of animal experiments confirmed its safety, NMN was gradually used in human clinical trials.

In 2022, a research team at DHC in Japan conducted a 12-week clinical trial to demonstrate that long-term oral supplementation of NMN is safe and also reduces brachial-ankle pulse wave velocity (baPWV), which is the elasticity of the arteries.

A total of 36 healthy participants were enrolled in the clinical trial, ranging in age from 40 to 59 years old and mostly female. Subjects were equally divided into NMN group and placebo group in double-blind condition, NMN group was given 125mg of NMN twice daily (total 250mg/ day) for 12 weeks, and placebo group was given placebo twice daily. After that, they were tested for various physical indicators and compared with those before the trial.

The results showed that oral NMN of 250mg/ day at 12 weeks did not cause adverse reactions, and there were no abnormalities in the basic physical indicators of the subjects.

In addition, NMN supplementation can also reduce brachial-ankle pulse wave conduction velocity (baPWV). Generally speaking, the lower the arterial elasticity, the higher the arm-ankle pulse wave conduction speed, and the higher the probability of cardiovascular disease.

The effect of NMN supplementation on the reduction of arm-ankle pulse wave velocity was particularly significant in subjects with higher than average BMI and blood glucose levels, and given that these populations are themselves at higher risk for cardiovascular disease, increasing arterial elasticity through NMN supplementation may have greater health implications for them.

In summary, this clinical trial confirmed the safety of supplementation with 250mg of NMN daily for 12 weeks and found that it increased the elasticity of arterial vessels.

This is also the first human clinical trial to find that NMN can help prevent cardiovascular disease, which may provide a safe and reliable preventive measure for obese people, diabetes patients and other people at risk of cardiovascular disease.

References:

1. Katayoshi, T., Uehata, S., Nakashima, N., Nakajo, T., Kitajima, N., Kageyama, M., & Tsuji-Naito, K. (2023). Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific reports, 13(1), 2786.

Previous:Explore NMN: A new hope for anti-aging

Next:Glutathione supplementation can reduce skin dark spots and wrinkles